IBA Dosimetry Americas Grows in Canada with Exclusive Distributor, ProMed Technologies
IBA Dosimetry Americas announces ProMed Technologies as their new, exclusive distributor partner for Canada, ensuring quality sales service in each province.
Bartlett, TN, USA, April 24, 2017 - IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of proton therapy solutions and radiation therapy quality assurance for the treatment of cancer, announces the Dosimetry Americas division has recently partnered with ProMed Technologies, Inc. as their exclusive distributor to grow sales service in Canada. ProMed Technologies will enable Canadian hospitals and cancer clinics to purchase the full range of IBA Dosimetry’s radiation therapy solutions, including myQA® software and their newest Patient QA transmission detector Dolphin®.
“We are extremely excited to collaborate with ProMed Technologies. The combination of IBA and ProMed Technologies will allow both companies to expand our market presence, provide exceptional support for the current IBA customer base, and better serve the important and dynamic Canadian Radiation Oncology market,” says Doug Utter, Director of Sales, Americas. “It is exciting partnering with a world class company with innovative products and exceptional customer support,” says Tony Giulione , President of ProMed Technologies.
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
About ProMed Technologies
ProMed Technologies was established in 1994, specializing in Medical sales in the Medical Physics and Biomedical engineering departments. The company’s mission statement is to be recognized as a leader in providing exceptional products and service in the Health Care Field. ProMed partners with IBA to provide existing and new customers in Canada the best in radiation therapy technology and service.